Xenon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has achieved a milestone in its pain genetics discovery collaboration with Genentech, triggering an undisclosed milestone payment. The companies have successfully discovered and identified a novel pain target leveraging Xenon’s Extreme Genetics platform based on the study of rare phenotypes of individuals who have either an inability to perceive pain or have spontaneous severe pain. “We are proud of our prog...